# Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

> **NCT01784068** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 215 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Nilotinib followed by treatment-free

## Key facts

- **NCT ID:** NCT01784068
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-19
- **Primary completion:** 2016-05-31
- **Final completion:** 2025-01-23
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784068, "Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01784068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*